DOCSLIB.ORG

Sample Thesis Title with a Concise and Accurate

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sample Thesis Title with a Concise and Accurate IDENTIFICATION OF THE POLYCOMB PROTEIN CBX2 AS A POTENTIAL DRUG TARGET IN ADVANCED PROSTATE CANCER AND BEYOND by Pier-Luc Clermont B.Sc. (Honours), McGill University, 2012 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in THE FACULTY OF GRADUATE AND POSTDOCTORAL STUDIES (Interdisciplinary Oncology) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) August 2015 © Pier-Luc Clermont, 2015 Abstract Globally, prostate cancer (PCa) represents the most commonly diagnosed cancer in men. While localized PCa can often be cured, all patients with metastatic disease inevitably develop castration-resistant prostate cancer (CRPC) or neuroendocrine prostate cancer (NEPC). Increasing evidence suggests that epigenetic alterations involving the Polycomb Group (PcG) family drive PCa progression. Although the PcG protein CBX2 is required for prostate development, its implication in human cancer remains unexplored. I therefore hypothesized that CBX2 may become deregulated during PCa progression and induce transcriptional programs promoting PCa aggressiveness. Using patient-derived xenografts and clinical datasets, I have explored the epigenetic landscape of advanced PCa and identified the Polycomb Group protein and epigenetic reader CBX2 as a potential drug target. First, CBX2 was significantly up-regulated in metastatic and castration- resistant PCa tissues. Furthermore, CBX2 overexpression predicted lower overall survival and correlated with numerous adverse prognostic factors. In addition, CBX2 depletion induced proliferation arrest and apoptosis in metastatic PCa cell lines, implying that CBX2 is required for PCa cell survival. Microarray analysis conducted after CBX2 silencing revealed that CBX2 regulates many genes controlling cellular proliferation and differentiation. Given the rising incidence of NEPC in advanced PCa, I analyzed whether CBX2 was also involved in NEPC pathogenesis. Strikingly, CBX2 was consistently the most highly up-regulated epigenetic regulator across multiple clinical and xenograft tumor tissues. Furthermore, I derived a list of 185 genes down-regulated in NEPC that was preferentially enriched in PcG target genes and predicted poor clinical outcome, in line with a critical function for CBX2 in late-stage PCa. Since CBX2 has never been linked to human cancers, I conducted a comprehensive meta-analysis of CBX2 across many tumor types using previously published clinical data. Strikingly, these studies demonstrated that the CBX2 locus is rarely inactivated or down-regulated. In contrast, CBX2 was frequently amplified and over-expressed in many common tumors, where it correlated with metastatic dissemination and poor clinical outcome. Overall, this work identifies CBX2 as novel epigenetic driver of cancer progression and investigates the therapeutic potential of CBX2 in advanced solid malignancies. ii Preface Tumor tissues were obtained from patients through a protocol approved by the Clinical Research Ethics Board of the University of British Columbia (UBC) and the BC Cancer Agency (BCCA). All patients signed a consent form approved by the Ethics Board (UBC Ethics Board #: H09- 01628 and H04-60131; VCHRI #: V09-0320 and V07-0058). Animal care and experimental procedures were carried out in accordance with the guidelines of the Canadian Council of Animal Care (CCAC) under the approval of the Animal Care Committee of University of British Columbia (permit #: A10-0100). Portions of Chapter 1 have been adapted from [Clermont PL], Crea F, Helgason CD. Chapter 22: Trithorax genes in prostate cancer. In "Advances in Prostate Cancer" (ISBN 978-953-51-0932-7; edited by Gerhard Hamilton), InTech, 2013. I am the original writer of all portions included. Crea F and Helgason CD critically revised the manuscript. A version of Chapter 2 is being prepared for publication. [Clermont PL], Crea F, Chiang YT, Lin D, Zhang A, Wang JZL, Parolia A, Wu R, Xue H, Wang Y, Ding J, Thu KL, Lam WL, Shah SP, Collins CC, Wang Y, Helgason CD. (2015, in preparation) Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer. I am first author of this manuscript. I designed experiments, collected and analyzed data, and wrote the manuscript. Lin D, Wu R, Xue H, Wang Y, and Wang Y were involved in the generation and characterization of the patient- derived xenograft models. Crea F, Chiang YT, Zhang A, Wang JZL, Parolia A, Ding J, and Thu KL provided assistance with experimental procedures and analysis. Lam WL, Shah SP, Collins CC, Wang Y, and Helgason CD critically revised the manuscript. A version of Chapters 1 and 3 has been accepted for publication. [Clermont PL], Lin D, Crea F, Wu R, Xue H, Wang Y, Thu KL, Lam WL, Collins CC, Wang Y, Helgason CD. (2015) Polycomb-mediated silencing in neuroendocrine prostate cancer. Clinical Epigenetics. I am first author of this manuscript. I designed experiments, collected and analyzed data, and wrote the manuscript. Lin D, Wu R, Xue H, Wang Y, and Wang Y were involved in the generation and characterization of the patient-derived xenograft models. Crea F and Thu KL provided assistance iii with experimental procedures and analysis. Lam WL, Collins CC, Wang Y, and Helgason CD critically revised the manuscript. A version of Chapters 1 and 4 has been published. [Clermont PL], Sun L, Crea F, Zhang A, Parolia A, Thu KL, Lam WL, Helgason CD. Genotranscriptomic meta-analysis of the polycomb gene CBX2 in human cancers: Initial evidence of an oncogenic role. British Journal of Cancer. 2014 Oct 14;111(8):1663-72. I am first author of this manuscript. I designed experiments, collected and analyzed data, and wrote the manuscript. Sun L, Crea F, Zhang A, Parolia A and Thu KL provided assistance with experimental procedures and analysis. Lam WL and Helgason CD critically revised the manuscript. iv Table of Contents Abstract .......................................................................................................................................... ii Preface ........................................................................................................................................... iii Table of Contents .......................................................................................................................... v List of Tables ................................................................................................................................. ix List of Figures ............................................................................................................................... xi List of Abbreviations .................................................................................................................. xiii Acknowledgements ...................................................................................................................... xv Dedication .................................................................................................................................. xvii 1. Introduction .............................................................................................................................. 1 1.1. Prostate cancer ................................................................................................................... 1 1.1.1. Overview .................................................................................................................... 1 1.1.2. Prostate development and physiology ........................................................................ 3 1.1.3. Prostate tumorigenesis and metastasis ....................................................................... 4 1.1.4. Clinical management .................................................................................................. 5 1.1.5. Castration-resistant prostate cancer ............................................................................ 6 1.1.6. Neuroendocrine prostate cancer ................................................................................. 8 1.1.7. Experimental models .................................................................................................. 9 1.2. Polycomb group complexes ............................................................................................ 11 1.2.1. Epigenetic control of transcription ........................................................................... 11 1.2.2. Composition and molecular mechanisms ................................................................. 13 1.2.3. Functions in development and cancer ...................................................................... 15 1.2.4. Polycomb-mediated silencing in prostate cancer ..................................................... 16 v 1.2.5. CBX gene family ...................................................................................................... 18 1.3. CBX2 ............................................................................................................................... 19 1.3.1. Structure and function .............................................................................................. 19 1.3.2. Roles in development ............................................................................................... 21 1.4. Thesis theme and rationale .............................................................................................. 23 1.5. Hypotheses and specific aims ........................................................................................
Load more

Recommended publications
  • Protein Interactions in the Cancer Proteome† Cite This: Mol
    Molecular BioSystems View Article Online PAPER View Journal | View Issue Small-molecule binding sites to explore protein– protein interactions in the cancer proteome† Cite this: Mol. BioSyst., 2016, 12,3067 David Xu,ab Shadia I. Jalal,c George W. Sledge Jr.d and Samy O. Meroueh*aef The Cancer Genome Atlas (TCGA) offers an unprecedented opportunity to identify small-molecule binding sites on proteins with overexpressed mRNA levels that correlate with poor survival. Here, we analyze RNA-seq and clinical data for 10 tumor types to identify genes that are both overexpressed and correlate with patient survival. Protein products of these genes were scanned for binding sites that possess shape and physicochemical properties that can accommodate small-molecule probes or therapeutic agents (druggable). These binding sites were classified as enzyme active sites (ENZ), protein–protein interaction sites (PPI), or other sites whose function is unknown (OTH). Interestingly, the overwhelming majority of binding sites were classified as OTH. We find that ENZ, PPI, and OTH binding sites often occurred on the same structure suggesting that many of these OTH cavities can be used for allosteric modulation of Creative Commons Attribution 3.0 Unported Licence. enzyme activity or protein–protein interactions with small molecules. We discovered several ENZ (PYCR1, QPRT,andHSPA6)andPPI(CASC5, ZBTB32,andCSAD) binding sites on proteins that have been seldom explored in cancer. We also found proteins that have been extensively studied in cancer that have not been previously explored with small molecules that harbor ENZ (PKMYT1, STEAP3,andNNMT) and PPI (HNF4A, MEF2B,andCBX2) binding sites. All binding sites were classified by the signaling pathways to Received 29th March 2016, which the protein that harbors them belongs using KEGG.
    [Show full text]
  • Mouse Cbx2 Knockout Project (CRISPR/Cas9)
    https://www.alphaknockout.com Mouse Cbx2 Knockout Project (CRISPR/Cas9) Objective: To create a Cbx2 knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Cbx2 gene (NCBI Reference Sequence: NM_007623 ; Ensembl: ENSMUSG00000025577 ) is located on Mouse chromosome 11. 5 exons are identified, with the ATG start codon in exon 1 and the TGA stop codon in exon 5 (Transcript: ENSMUST00000026662). Exon 4 will be selected as target site. Cas9 and gRNA will be co-injected into fertilized eggs for KO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Mutations cause malformations of the axial skeletal, reduced viability, poor growth and male to female sex reversal. Exon 4 starts from about 11.75% of the coding region. Exon 4 covers 6.81% of the coding region. The size of effective KO region: ~106 bp. The KO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele gRNA region 5' gRNA region 3' 1 4 5 Legends Exon of mouse Cbx2 Knockout region Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot (up) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 2000 bp section upstream of Exon 4 is aligned with itself to determine if there are tandem repeats. No significant tandem repeat is found in the dot plot matrix. So this region is suitable for PCR screening or sequencing analysis. Overview of the Dot Plot (down) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 1343 bp section downstream of Exon 4 is aligned with itself to determine if there are tandem repeats.
    [Show full text]
  • Protein Quality Control in the Nucleolus Safeguards Recovery of Epigenetic
    RESEARCH ARTICLE Protein quality control in the nucleolus safeguards recovery of epigenetic regulators after heat shock Maria Azkanaz1, Aida Rodrı´guezLo´ pez1, Bauke de Boer1, Wouter Huiting2, Pierre-Olivier Angrand3, Edo Vellenga1, Harm H Kampinga2, Steven Bergink2, Joost HA Martens4, Jan Jacob Schuringa1†, Vincent van den Boom1†* 1Department of Experimental Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; 2Department of Biomedical Sciences of Cells and Systems, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; 3Cell Plasticity & Cancer, Inserm U908, University of Lille, Lille, France; 4Department of Molecular Biology, Faculty of Science and Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, Nijmegen, Netherlands Abstract Maintenance of epigenetic modifiers is of utmost importance to preserve the epigenome and consequently appropriate cellular functioning. Here, we analyzed Polycomb group protein (PcG) complex integrity in response to heat shock (HS). Upon HS, various Polycomb Repressive Complex (PRC)1 and PRC2 subunits, including CBX proteins, but also other chromatin regulators, are found to accumulate in the nucleolus. In parallel, binding of PRC1/2 to target genes is strongly reduced, coinciding with a dramatic loss of H2AK119ub and H3K27me3 marks. Nucleolar-accumulated CBX proteins are immobile, but remarkably both CBX protein accumulation and loss of PRC1/2 epigenetic marks are reversible. This post-heat shock recovery of pan-nuclear CBX protein localization and reinstallation of epigenetic marks is HSP70 dependent. Our findings *For correspondence: demonstrate that the nucleolus is an essential protein quality control center, which is indispensable [email protected] for recovery of epigenetic regulators and maintenance of the epigenome after heat shock.
    [Show full text]
  • Evolutionarily Ancient BAH–PHD Protein Mediates Polycomb Silencing
    Evolutionarily ancient BAH–PHD protein mediates Polycomb silencing Elizabeth T. Wilesa,1, Kevin J. McNaughta,1, Gurmeet Kaurb, Jeanne M. L. Selkera, Tereza Ormsbya,2, L. Aravindb, and Eric U. Selkera,3 aInstitute of Molecular Biology, University of Oregon, Eugene, OR 97403; and bNational Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894 Contributed by Eric U. Selker, March 18, 2020 (sent for review October 28, 2019; reviewed by Wolfgang Fischle and Steve Jacobsen) Methylation of histone H3 lysine 27 (H3K27) is widely recognized (NCU07505) that we show is critical for H3K27 methylation- as a transcriptionally repressive chromatin modification but the mediated silencing and therefore named it effector of Polycomb re- mechanism of repression remains unclear. We devised and imple- pression 1 (epr-1). It encodes a protein with a bromo-adjacent ho- mented a forward genetic scheme to identify factors required for mology (BAH) domain and plant homeodomain (PHD) finger. H3K27 methylation-mediated silencing in the filamentous fungus Although epr-1 mutants display phenotypic and gene-expression Neurospora crassa and identified a bromo-adjacent homology changes similar to strains lacking PRC2 components, H3K27 meth- (BAH)-plant homeodomain (PHD)-containing protein, EPR-1 (effec- ylation is essentially unaffected. We demonstrate that EPR-1 forms tor of polycomb repression 1; NCU07505). EPR-1 associates with nuclear foci, reminiscent of Polycomb bodies (24), and its genomic H3K27-methylated chromatin, and loss of EPR-1 de-represses H3K27- distribution is limited to, and dependent upon, H3K27-methylated methylated genes without loss of H3K27 methylation. EPR-1 is not chromatin, which may be recognized through its BAH domain.
    [Show full text]
  • RYBP-PRC1 Complexes Mediate H2A Ubiquitylation at Polycomb Target Sites Independently of PRC2 and H3k27me3
    RYBP-PRC1 Complexes Mediate H2A Ubiquitylation at Polycomb Target Sites Independently of PRC2 and H3K27me3 Lı´gia Tavares,1 Emilia Dimitrova,2 David Oxley,3 Judith Webster,3 Raymond Poot,4 Jeroen Demmers,5 Karel Bezstarosti,5 Stephen Taylor,6 Hiroki Ura,7 Hiroshi Koide,7 Anton Wutz,8 Miguel Vidal,9 Sarah Elderkin,2,* and Neil Brockdorff1,* 1Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK 2Nuclear Dynamics 3Mass Spectrometry Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK 4Department of Cell Biology 5Proteomics Center Erasmus Medical Center, Dr. Molewaterplein 50, 3015GE Rotterdam, The Netherlands 6Computational Biology Research Group, WIMM, University of Oxford, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK 7Department of Stem Cell Biology, Graduate School of Medical Science, Kanazawa University, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8640, Japan 8Wellcome Trust Centre for Stem Cell Research, Tennis Court Road, Cambridge CB2 1QR, UK 9Cell Proliferation and Development, Centro de Investigaciones Biolo´ gicas, Consejo Superior de Investigaciones Cientificas (CSIC), 28040 Madrid, Spain *Correspondence: [email protected] (S.E.), [email protected] (N.B.) DOI 10.1016/j.cell.2011.12.029 SUMMARY histone-modifying activity critical for their function in gene re- pression, monoubiquitylation of histone H2AK119 (H2AK119u1), Polycomb-repressive complex 1 (PRC1) has a central and di- tri-methylation of histone H3K27, respectively (reviewed role in the regulation of heritable gene silencing in Mu¨ ller and Verrijzer, 2009). Mechanisms other than H2A during differentiation and development. PRC1 re- ubiquitylation also contribute to PRC1-mediated gene repression cruitment is generally attributed to interaction of (Eskeland et al., 2010; Francis et al., 2001, 2004; King et al., 2002; the chromodomain of the core protein Polycomb Shao et al., 1999).
    [Show full text]
  • Investigating the Role of CBX2 in ER- Positive Breast Cancer
    Investigating the role of CBX2 in ER- positive breast cancer Ella Jane Waters 201501212 MSc by Research Supervisor: Dr Mark Wade Second Supervisor: Dr Cheryl Walter Date: 24/09/2019 Faculty of Health Science Acknowledgements I would like to thank Dr Mark Wade for facilitating this project, being a great supervisor and for his continued guidance and support throughout. I would also like to thank Dr Cheryl Walter for the additional and valuable assistance, and for her kind words and support. Additionally, I would like to thank Chloe Warren for her continued encouragement and help in the laboratory. I would also like to thank Mrs Kath Bulmer, Dr Pedro Beltran-Alvarez and Dr Barbara Guinn for their knowledge and experience. I finally want to thank my family and friends for their patience and support throughout this year. i Abstract Breast cancer is the most common form of cancer in women, with oestrogen receptor (ER) positive breast cancers being the most common subtype. Although there are targeted endocrine therapies for this receptor, resistance mechanisms mean that they are not always effective. Post-translational modifications of histone proteins are important for regulating gene expression. It is known that the pattern of modifications is different in cancerous tissue compared to normal tissue. Epigenetic reader proteins recognise histone post-translational modifications and help remodel the adjacent chromatin landscape, resulting in gene expression or repression. This means epigenetic reader proteins are possible novel therapeutic targets. CBX2 is an example of an epigenetic reader protein which is overexpressed in ER-positive breast cancer. The aim of this study was to analyse the role of CBX2 in ER-positive breast cancer.
    [Show full text]
  • A Chromosome-Centric Human Proteome Project (C-HPP) To
    computational proteomics Laboratory for Computational Proteomics www.FenyoLab.org E-mail: [email protected] Facebook: NYUMC Computational Proteomics Laboratory Twitter: @CompProteomics Perspective pubs.acs.org/jpr A Chromosome-centric Human Proteome Project (C-HPP) to Characterize the Sets of Proteins Encoded in Chromosome 17 † ‡ § ∥ ‡ ⊥ Suli Liu, Hogune Im, Amos Bairoch, Massimo Cristofanilli, Rui Chen, Eric W. Deutsch, # ¶ △ ● § † Stephen Dalton, David Fenyo, Susan Fanayan,$ Chris Gates, , Pascale Gaudet, Marina Hincapie, ○ ■ △ ⬡ ‡ ⊥ ⬢ Samir Hanash, Hoguen Kim, Seul-Ki Jeong, Emma Lundberg, George Mias, Rajasree Menon, , ∥ □ △ # ⬡ ▲ † Zhaomei Mu, Edouard Nice, Young-Ki Paik, , Mathias Uhlen, Lance Wells, Shiaw-Lin Wu, † † † ‡ ⊥ ⬢ ⬡ Fangfei Yan, Fan Zhang, Yue Zhang, Michael Snyder, Gilbert S. Omenn, , Ronald C. Beavis, † # and William S. Hancock*, ,$, † Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States ‡ Stanford University, Palo Alto, California, United States § Swiss Institute of Bioinformatics (SIB) and University of Geneva, Geneva, Switzerland ∥ Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States ⊥ Institute for System Biology, Seattle, Washington, United States ¶ School of Medicine, New York University, New York, United States $Department of Chemistry and Biomolecular Sciences, Macquarie University, Sydney, NSW, Australia ○ MD Anderson Cancer Center, Houston, Texas, United States ■ Yonsei University College of Medicine, Yonsei University,
    [Show full text]
  • RYBP Stimulates PRC1 to Shape Chromatin-Based
    RESEARCH ARTICLE RYBP stimulates PRC1 to shape chromatin-based communication between Polycomb repressive complexes Nathan R Rose1†, Hamish W King1†, Neil P Blackledge1†, Nadezda A Fursova1, Katherine JI Ember1, Roman Fischer2, Benedikt M Kessler2,3, Robert J Klose1,3* 1Department of Biochemistry, University of Oxford, Oxford, United Kingdom; 2TDI Mass Spectrometry Laboratory, Target Discovery Institute, University of Oxford, Oxford, United Kingdom; 3Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom Abstract Polycomb group (PcG) proteins function as chromatin-based transcriptional repressors that are essential for normal gene regulation during development. However, how these systems function to achieve transcriptional regulation remains very poorly understood. Here, we discover that the histone H2AK119 E3 ubiquitin ligase activity of Polycomb repressive complex 1 (PRC1) is defined by the composition of its catalytic subunits and is highly regulated by RYBP/YAF2- dependent stimulation. In mouse embryonic stem cells, RYBP plays a central role in shaping H2AK119 mono-ubiquitylation at PcG targets and underpins an activity-based communication between PRC1 and Polycomb repressive complex 2 (PRC2) which is required for normal histone H3 lysine 27 trimethylation (H3K27me3). Without normal histone modification-dependent communication between PRC1 and PRC2, repressive Polycomb chromatin domains can erode, rendering target genes susceptible to inappropriate gene expression signals. This suggests that activity-based communication and histone modification-dependent thresholds create a localized *For correspondence: rob.klose@ form of epigenetic memory required for normal PcG chromatin domain function in gene regulation. bioch.ox.ac.uk DOI: 10.7554/eLife.18591.001 †These authors contributed equally to this work Competing interests: The authors declare that no Introduction competing interests exist.
    [Show full text]
  • A Cellular Chemical Probe Targeting the Chromodomains of Polycomb
    ARTICLE PUbliShED oNliNE: 25 JANUARy 2016 | Doi: 10.1038/NchEmbio.2007 A cellular chemical probe targeting the chromodomains of Polycomb repressive complex 1 Jacob I Stuckey1, Bradley M Dickson1, Nancy Cheng1, Yanli Liu2, Jacqueline L Norris1, Stephanie H Cholensky1, Wolfram Tempel2, Su Qin2, Katherine G Huber1, Cari Sagum3, Karynne Black3, Fengling Li2, Xi-Ping Huang4,5, Bryan L Roth4,5, Brandi M Baughman1, Guillermo Senisterra2, Samantha G Pattenden1, Masoud Vedadi2, Peter J Brown2, Mark T Bedford3, Jinrong Min2, Cheryl H Arrowsmith2, Lindsey I James1,* & Stephen V Frye1,* We report the design and characterization of UNC3866, a potent antagonist of the methyllysine (Kme) reading function of the Polycomb CBX and CDY families of chromodomains. Polycomb CBX proteins regulate gene expression by targeting Polycomb repressive complex 1 (PRC1) to sites of H3K27me3 via their chromodomains. UNC3866 binds the chromodomains of CBX4 and CBX7 most potently, with a Kd of ~100 nM for each, and is 6- to 18-fold selective as compared to seven other CBX and CDY chromodo- mains while being highly selective over >250 other protein targets. X-ray crystallography revealed that UNC3866’s interactions with the CBX chromodomains closely mimic those of the methylated H3 tail. UNC4195, a biotinylated derivative of UNC3866, was used to demonstrate that UNC3866 engages intact PRC1 and that EED incorporation into PRC1 is isoform dependent in PC3 prostate cancer cells. Finally, UNC3866 inhibits PC3 cell proliferation, consistent with the known ability of CBX7 overexpression to confer a growth advantage, whereas UNC4219, a methylated negative control compound, has negligible effects. ethylation of lysine residues on histones critically contrib- the complexity of PRC1, it was recently reported that EED, the utes to chromatin regulation1,2.
    [Show full text]
  • Transcriptional Regulation of the Testis-Determining Gene Sry Christian Larney, Timothy L
    © 2014. Published by The Company of Biologists Ltd | Development (2014) 141, 2195-2205 doi:10.1242/dev.107052 REVIEW Switching on sex: transcriptional regulation of the testis-determining gene Sry Christian Larney, Timothy L. Bailey and Peter Koopman* ABSTRACT express Sry and adopt a male fate in response to molecular signals Mammalian sex determination hinges on the development of ovaries arising from Sertoli cells. Sry expression is detectable in mice from or testes, with testis fate being triggered by the expression of the 10.5 days post-coitum (dpc) (Koopman et al., 1990; Hacker et al., transcription factor sex-determining region Y (Sry). Reduced or 1995; Jeske et al., 1996) and is initially restricted to the central region delayed Sry expression impairs testis development, highlighting the of the gonad (Bullejos and Koopman, 2001). This region of Sry importance of its accurate spatiotemporal regulation and implying a expression then rapidly expands to encompass the entire gonad at ∼ potential role for SRY dysregulation in human intersex disorders. 11.5 dpc (Fig. 1D) before being extinguished, first in the central Several epigenetic modifiers, transcription factors and kinases are region and then outwards towards the poles. Expression is implicated in regulating Sry transcription, but it remains unclear undetectable by 12.5 dpc. This expression profile appears to place whether or how this farrago of factors acts co-ordinately. Here we testis determination on a knife edge, with slight decreases in Sry review our current understanding of Sry regulation and provide a expression levels, or delays of peak expression by as little as a few model that assembles all known regulators into three modules, each hours, leading to failure of the testis-determining pathway and converging on a single transcription factor that binds to the Sry malapropos development of either ovotestes or ovaries (Hiramatsu promoter.
    [Show full text]
  • A Central Role for Canonical PRC1 in Shaping the 3D Nuclear Landscape
    Downloaded from genesdev.cshlp.org on October 7, 2021 - Published by Cold Spring Harbor Laboratory Press A central role for canonical PRC1 in shaping the 3D nuclear landscape Shelagh Boyle,2 Ilya M. Flyamer,2 Iain Williamson, Dipta Sengupta, Wendy A. Bickmore, and Robert S. Illingworth1 MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, United Kingdom Polycomb group (PcG) proteins silence gene expression by chemically and physically modifying chromatin. A subset of PcG target loci are compacted and cluster in the nucleus; a conformation that is thought to contribute to gene silencing. However, how these interactions influence gross nuclear organization and their relationship with tran- scription remains poorly understood. Here we examine the role of Polycomb-repressive complex 1 (PRC1) in shaping 3D genome organization in mouse embryonic stem cells (mESCs). Using a combination of imaging and Hi-C anal- yses, we show that PRC1-mediated long-range interactions are independent of CTCF and can bridge sites at a megabase scale. Impairment of PRC1 enzymatic activity does not directly disrupt these interactions. We demon- strate that PcG targets coalesce in vivo, and that developmentally induced expression of one of the target loci dis- rupts this spatial arrangement. Finally, we show that transcriptional activation and the loss of PRC1-mediated interactions are separable events. These findings provide important insights into the function of PRC1, while highlighting the complexity of this regulatory system. [Keywords: polycomb; topologically associating domains (TADs); gene repression; nuclear organization; embryonic stem cells; gene regulation; epigenetics; histone modifications] Supplemental material is available for this article.
    [Show full text]
  • Bioinformatic Analysis of the Expression and Prognostic Value Of
    www.nature.com/scientificreports OPEN Bioinformatic analysis of the expression and prognostic value of chromobox family proteins in human breast cancer Xiaomin Li1,3, Junhe Gou2, Hongjiang Li3 & Xiaoqin Yang3* Chromobox (CBX) family proteins control chromatin structure and gene expression. However, the functions of CBXs in cancer progression, especially breast cancer, are inadequately studied. We assessed the signifcance of eight CBX proteins in breast cancer. We performed immunohistochemistry and bioinformatic analysis of data from Oncomine, GEPIA Dataset, bcGenExMiner, Kaplan–Meier Plotter, and cBioPortal. We compared mRNA and protein expression levels of eight CBX proteins between breast tumor and normal tissue. The expression diference of CBX7 was the greatest, and CBX7 was downregulated in breast cancer tissues compared with normal breast tissues. The expression of CBX2 was strongly associated with tumor stage. We further analyzed the association between the eight CBX proteins and the following clinicopathological features: menopause age, estrogen receptor (ER), progesterone receptor (PR) and HER-2 receptor status, nodal status, P53 status, triple-negative status, and the Scarf–Bloom–Richardson grade (SBR) and Nottingham prognostic index (NPI). Survival analysis in the Kaplan–Meier Plotter database showed that the eight CBX proteins were signifcantly associated with prognosis. Moreover, CBX genes in breast cancer patients had a high net alteration frequency of 57%. There were signifcant co-expression correlations between the following CBX protein pairs: CBX4 positively with CBX8, CBX6 positively with CBX7, and CBX2 negatively with CBX7. We also analyzed the Gene Ontology enrichment of the CBX proteins, including biological processes, cellular components, and molecular functions. CBX 1/2/3/5/8 may be oncogenes for breast cancer, whereas CBX 6 and 7 may be tumor suppressors for breast cancer.
    [Show full text]